Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb 3:14:1131057.
doi: 10.3389/fimmu.2023.1131057. eCollection 2023.

Precision-engineering of subunit vaccine particles for prevention of infectious diseases

Shuxiong Chen  1 , Saranya Pounraj  1 , Nivethika Sivakumaran  1 , Anjali Kakkanat  1 , Gayathri Sam  1 , Md Tanvir Kabir  1 , Bernd H A Rehm  1   2
Affiliations
Review

Precision-engineering of subunit vaccine particles for prevention of infectious diseases

Shuxiong Chen et al. Front Immunol. .

Abstract

Vaccines remain the best approach for the prevention of infectious diseases. Protein subunit vaccines are safe compared to live-attenuated whole cell vaccines but often show reduced immunogenicity. Subunit vaccines in particulate format show improved vaccine efficacy by inducing strong immune responses leading to protective immunity against the respective pathogens. Antigens with proper conformation and function are often required to induce functional immune responses. Production of such antigens requiring post-translational modifications and/or composed of multiple complex domains in bacterial hosts remains challenging. Here, we discuss strategies to overcome these limitations toward the development of particulate vaccines eliciting desired humoral and cellular immune responses. We also describe innovative concepts of assembling particulate vaccine candidates with complex antigens bearing multiple post-translational modifications. The approaches include non-covalent attachments (e.g. biotin-avidin affinity) and covalent attachments (e.g. SpyCatcher-SpyTag) to attach post-translationally modified antigens to particles.

Keywords: cross-presentation; dendritic cells; infectious diseases; particulate vaccine; post-translational modification; protective immunity.

PubMed Disclaimer

Conflict of interest statement

Author BHAR is an inventor of the biopolymer particle technology and co-founder/shareholder of Polybatics Ltd. BHAR and SC are inventors on a patent application describing the immunogenic carrier protein CRM197 vaccine platform and its uses. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Comparison of antigen processing pathways elicited by soluble and particulate antigen formulations.
Figure 2
Figure 2
Flow diagram of precision-engineering of subunit vaccine particles.
See this image and copyright information in PMC

References

    1. Gonzalez-Miro M, Chen S, Gonzaga ZJ, Evert B, Wibowo D, Rehm BH. Polyester as antigen carrier toward particulate vaccines. Biomacromolecules (2019) 20(9):3213–32. doi: 10.1021/acs.biomac.9b00509 - DOI - PubMed
    1. Tao P, Zhu J, Mahalingam M, Batra H, Rao VB. Bacteriophage T4 nanoparticles for vaccine delivery against infectious diseases. Adv Drug Deliv Rev (2019) 145:57–72. doi: 10.1016/j.addr.2018.06.025 - DOI - PMC - PubMed
    1. Seyfoori A, Shokrollahi Barough M, Mokarram P, Ahmadi M, Mehrbod P, Sheidary A, et al. . Emerging advances of nanotechnology in drug and vaccine delivery against viral associated respiratory infectious diseases (Varid). Int J Mol Sci (2021) 22(13):6937. doi: 10.3390/ijms22136937 - DOI - PMC - PubMed
    1. Pielenhofer J, Sohl J, Windbergs M, Langguth P, Radsak MP. Current progress in particle-based systems for transdermal vaccine delivery. Front Immunol (2020) 11:266. doi: 10.3389/fimmu.2020.00266 - DOI - PMC - PubMed
    1. Snapper CM. Distinct immunologic properties of soluble versus particulate antigens. Front Immunol (2018) 9:598. doi: 10.3389/fimmu.2018.00598 - DOI - PMC - PubMed

Publication types